Amgen’s Erenumab Lessens Monthly Migraines in Phase II Trial

A global Phase II trial showed that erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine.

The study included 667 patients randomized to receive placebo or subcutaneous erenumab 70 mg or 140 mg once a month. Patients randomized to both erenumab dose groups experienced a 6.6-day reduction in average monthly migraine days, compared with 4.2 days in the placebo group.

A reduction of 50 percent or more in number of monthly migraine days was observed in about 40 percent of individuals in the erenumab groups after 12 weeks.

Amgen, the drug’s sponsor, presented the data at the European Headache and Migraine Trust International Congress in Glasgow, Scotland.